Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HAO 
Haoxi Health Technology Limited Class A Ordinary Shares (HAO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: HAO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.38% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.28 | 52 Weeks Range 1.02 - 173.25 | Updated Date 06/29/2025 |
52 Weeks Range 1.02 - 173.25 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.61% | Operating Margin (TTM) -0.53% |
Management Effectiveness
Return on Assets (TTM) 3.42% | Return on Equity (TTM) 2.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4130603 | Price to Sales(TTM) 0.08 |
Enterprise Value -4130603 | Price to Sales(TTM) 0.08 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA 17.37 | Shares Outstanding 2205800 | Shares Floating 1686284 |
Shares Outstanding 2205800 | Shares Floating 1686284 | ||
Percent Insiders 21.79 | Percent Institutions 5.78 |
Upturn AI SWOT
Haoxi Health Technology Limited Class A Ordinary Shares
Company Overview
History and Background
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) is a China-based company focused on providing online healthcare services. The company was formerly known as China Internet Nationwide Financial Services Inc. and changed its name in May 2021. It offers services through its online platform, aiming to improve access to healthcare for individuals in China.
Core Business Areas
- Online Healthcare Platform: Provides a platform connecting patients with doctors, offering online consultations, prescriptions, and health management services.
- Pharmaceutical E-commerce: Facilitates the online sale of prescription and over-the-counter medications.
- Digital Healthcare Solutions: Offers digital healthcare solutions for chronic disease management and other health-related needs.
Leadership and Structure
Information regarding the specific leadership team and organizational structure would require access to up-to-date company filings or official statements. Without access, this data cannot be accurately populated.
Top Products and Market Share
Key Offerings
- Online Consultation Services: Connecting patients with doctors for remote consultations. Market share information is not readily available and requires specialized market research. Competitors include Ping An Good Doctor and Ali Health.
- E-Pharmacy: Selling prescription and OTC drugs online. Market share data requires specific market research. Competitors include JD Health and 1 Drugstore.
- Chronic Disease Management: Providing digital tools and support for patients with chronic conditions. Market share and revenue data require specialized market research. Competitors include DXY and WeDoctor.
Market Dynamics
Industry Overview
The online healthcare industry in China is experiencing rapid growth, driven by increasing internet penetration, government support, and a growing demand for convenient healthcare services. Regulatory changes and intense competition characterize the market.
Positioning
Haoxi Health Technology Limited Class A Ordinary Shares aims to be a key player in China's online healthcare market, leveraging its technology platform and partnerships to provide comprehensive healthcare solutions.
Total Addressable Market (TAM)
The TAM for China's online healthcare market is estimated to be in the hundreds of billions of dollars. Haoxi Health is positioned to capture a share of this market by focusing on underserved regions and niche healthcare needs.
Upturn SWOT Analysis
Strengths
- Established online platform
- Growing user base
- Strategic partnerships with healthcare providers
Weaknesses
- Limited brand recognition compared to larger competitors
- Dependence on regulatory environment
- Profitability concerns
Opportunities
- Expanding into new geographic regions
- Developing innovative healthcare solutions
- Capitalizing on government support for online healthcare
Threats
- Intense competition from established players
- Changing regulatory landscape
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- Ping An Healthcare and Technology (1833.HK)
- JD Health (6618.HK)
- Alibaba Health Information Technology (0241.HK)
Competitive Landscape
Haoxi Health faces significant competition from larger, more established players. Its ability to differentiate itself through specialized services and partnerships will be crucial for success.
Growth Trajectory and Initiatives
Historical Growth: Information regarding historical growth rates would require access to historical financial databases or company filings.
Future Projections: Future growth projections require analyst estimates which are not readily available without a subscription to a financial data provider.
Recent Initiatives: Recent initiatives would be best obtained from company press releases and investor presentations, which require accessing external data sources.
Summary
Haoxi Health is a developing player in the growing Chinese online healthcare market. While it has established an online platform and is focusing on partnerships, the company faces strong competition from established giants. Its future success depends on navigating regulatory hurdles, differentiating its offerings, and achieving profitability. Haoxi Health needs to concentrate on building brand awareness and acquiring new customers to stay relevant in this highly contested landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (Unavailable in this context)
- Market Research Reports (Unavailable in this context)
- Industry News Articles
Disclaimers:
The information provided is based on publicly available information and general industry knowledge. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and professional advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haoxi Health Technology Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2008-01-30 | Chairman & CEO Mr. Zhen Fan | ||
Sector Communication Services | Industry Advertising Agencies | Full time employees 30 | Website https://www.haoximedia.com |
Full time employees 30 | Website https://www.haoximedia.com | ||
Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. The company offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. It places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. The company serves advertiser client base primarily in the healthcare industry. Haoxi Health Technology Limited was founded in 2018 and is based in Chaoyang, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.